Hanbury FZE
  • Search
  • Home
  • Products & Services
    • Nutraceutical Ingredients
      • Standardized Phyto Extracts
      • Beverage/Liquid Dietary Supplements
      • GRAS Affirmed Ingredients
      • Minerals for Nutritional Use
      • Phytochemicals for Nutritional Use
      • Multi-enzyme Blends
      • Natural Protein
      • Nutritional Fine Chemicals
      • Phyto Functional Blends
      • Geroceuticals™
      • Prebiotics, Probiotics, Postbiotics and Synbiotics
      • Super Critical Fluid (SCF) Extracts
      • Specialty Fine Chemicals
    • Cosmeceutical Ingredients
      • Natural Actives
      • Peptides
      • Anti-Glycation
      • Dermaceuticals
      • Nutricosmetics
      • Probiotics & Postbiotics
      • Proprietary Cosmeceutical Blends
      • Speciality Chemicals
    • Services
      • Custom Manufacturing
      • Contract Manufacturing
      • Product Specification Sheet
    • Pharma
      • Natural Drugs
      • Chiral Drug Intermediates
  • About Us
    • Our Story
    • Our People
    • Research & Development
    • Manufacturing Facilities
    • Intellectual Properties
  • Newsroom
    • Press Release
    • FAQs
      • BioPerine®
      • Citrin®K
      • Cococin™
      • Curcumin C3 Complex®
      • Curcumin C3 Reduct®
      • ForsLean®
      • GarCitrin®
      • LactoSpore®
      • LeanGard®
  • Contact Us

Home / Sami-Sabinsa’s Pterocarpus Marsupium Reforestation Program Named Industry Initiative of The Year Award Finalist

Sami-Sabinsa’s Pterocarpus Marsupium Reforestation Program Named Industry Initiative of The Year Award Finalist

Sami-Sabinsa’s Pterocarpus Marsupium Reforestation Program Named Industry Initiative of The Year Award Finalist

The Sami-Sabinsa Group’s ambitious 10-year reforestation program of Pterocarpus Marsupium trees in India has been chosen as one of two finalists in the NutraIngredients-USA Editors Award for Industry Initiative of the Year. The winner will be announced at an event in Chicago on July 16, 2018.

This reforestation program is the first of its kind in the herbal industry: proactively addressing future supply shortfall of a medicinal tree. Anticipating future demand as research confirms traditional Ayurvedic use for diabetes, Sami-Sabinsa learned that the Indian Kino tree population is threatened. Sami-Sabinsa developed and funded a collaborative program to plant 166,600 trees on 250 forest acres over ten years, the first conservation program for this high value threatened tree species in India. Sami-Sabinsa is conceived and funded the initiative, with cultivation managed by the reforestation organization Madhya Pradesh Rajya Van Vikas Nigam Limited on land provided by the forest department of the State of Madhya Pradesh.

Based on International Union for Conservation of Nature criteria, India’s Foundation for Revitalisation of Local Health Traditions evaluated the Indian Kino tree populations in various states in India and put the species in categories ranging from ‘Critically endangered’ to ‘Vulnerable’ depending upon region.

“We are honored that our reforestation program has been recognized as significant by the respected industry publication NutraIngredients-USA,” said Shaheen Majeed, Sabinsa’s worldwide president. “We hope that this innovative program will serve as a model for the industry to take a proactive, longer-term view of the botanical ingredients supply chain.”

Sabinsa’s proprietary ingredient extracts obtained from Pterocarpus Marsupium, and based upon licensed patents, are sold under the brand names, Silbinol® and pTeroSol®.

Back
top

HEADQUARTERS

Hanbury FZE


Jebel Ali Free Zone


Warehouse No. RA08AB05


P O Box. 61091


Dubai


United Arab Emirates


+971 4 883 8981

+971 4 883 8978

mail@hanburyfze.ae

CERTIFICATES

Certificate Logos Certificate Logos Certificate LogosCertificate Logos

Global Contacts List

USA India
Utah, USA Japan
Australia Poland
Brasil Korea
Canada South Africa
China Vietnam
Germany  

CONTACT US

    © 2023 Hanbury FZE. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Terms of Use | Sitemap | Disclaimer

    • Facebook
    • Twitter
    • LinkedIn
    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.